Literature DB >> 32280146

Are We Able to Dose Protamine Accurately Yet? A Review of the Protamine Conundrum.

Patrick Hecht1, Martin Besser2, Florian Falter3.   

Abstract

Without anticoagulation, cardiopulmonary bypass would not have developed over the last nearly 60 years into one of the most influential innovations in medicine; without the ability to reverse anticoagulation, cardiac surgery might not have become the common intervention, which is now practiced globally. Despite the recent breathtaking developments in extracorporeal technology, heparin and protamine remain the pillars of anticoagulation and its reversal until this day. However, there is still much controversy in particular about protamine dosing regimens. A number of recent publications investigating various approaches to dosing protamine have rekindled this debate. This review is seeking to capture the current thinking about protamine dosing after cessation of cardiopulmonary bypass. © Copyright 2020 AMSECT.

Entities:  

Keywords:  anticoagulation; cardiopulmonary bypass; heparin; protamine

Mesh:

Substances:

Year:  2020        PMID: 32280146      PMCID: PMC7138116          DOI: 10.1182/ject-1900038

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  63 in total

1.  The precipitation of fibrinogen by heparin at pH 4.8.

Authors:  I J TEMPERLEY
Journal:  Ir J Med Sci       Date:  1963-04       Impact factor: 1.568

Review 2.  Protamine and protamine reactions.

Authors:  Kyung W Park
Journal:  Int Anesthesiol Clin       Date:  2004

3.  A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass.

Authors:  Michael I Meesters; Dennis Veerhoek; Jan R de Jong; Christa Boer
Journal:  J Cardiothorac Vasc Anesth       Date:  2016-04-28       Impact factor: 2.628

4.  Exogenous 35S-labeled heparin: organ distribution and metabolism.

Authors:  T Stau; J Metz; R Taugner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

5.  Clinical Evaluation of Measuring the ACT during Elective Cardiac Surgery with Two Different Devices.

Authors:  Florian Falter; Nabeel Razzaq; Martin John; Jens Fassl; Markus Maurer; Sean Ewing; Ross Hofmeyr
Journal:  J Extra Corpor Technol       Date:  2018-03

6.  Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?

Authors:  Kevin H T Teoh; Edward Young; Mary Helen Blackall; Robin S Roberts; Jack Hirsh
Journal:  J Thorac Cardiovasc Surg       Date:  2004-08       Impact factor: 5.209

7.  Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time.

Authors:  P D Raymond; M J Ray; S N Callen; N A Marsh
Journal:  Perfusion       Date:  2003-09       Impact factor: 1.972

8.  Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery.

Authors:  J R Zaidan; S Johnson; R Brynes; S Monroe; A V Guffin
Journal:  Anesth Analg       Date:  1986-04       Impact factor: 5.108

9.  Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: results of a randomized double-blind controlled pilot study.

Authors:  Andreas Koster; Jochen Börgermann; Jan Gummert; Markus Rudloff; Armin Zittermann; Uwe Schirmer
Journal:  Clin Appl Thromb Hemost       Date:  2013-04-04       Impact factor: 2.389

10.  A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.

Authors:  Robert D Slight; Rivan Buell; Onyekwelu C Nzewi; David B L McClelland; Pankaj S Mankad
Journal:  J Cardiothorac Vasc Anesth       Date:  2007-11-07       Impact factor: 2.628

View more
  2 in total

1.  Can the Minimum Protamine Dose to Neutralize Heparin at the Completion of Cardiopulmonary Bypass be Significantly Lower than the Conventional Practice?

Authors:  Min-Ho Lee; William Riley; Kenneth G Shann
Journal:  J Extra Corpor Technol       Date:  2021-09

Review 2.  Use of Protamine in Nanopharmaceuticals-A Review.

Authors:  Ivana Ruseska; Katja Fresacher; Christina Petschacher; Andreas Zimmer
Journal:  Nanomaterials (Basel)       Date:  2021-06-07       Impact factor: 5.076

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.